Des résultats prometteurs pour les immunothérapies anticancéreuses !

Promising news on the immunotherapies front! Impressive results have been published last week regarding two new immunotherapies, pembrolizumab and nivolumab, treating patients diagnosed with melanoma, non-small cell lung cancer and renal cancer.

Data from phase 3 trials for the breakthrough immunotherapies pembrolizumab and nivolumab have shown exiting results for the treatment of melanoma, non-small cell lung cancer and renal cancer. The data was presented last week at the convention of the American Society of Clinical Oncology (ASCO) 2015.

Many media have reported about these results, a short overview can be found below:

• New Class of Drugs Shows More Promise in Treating Cancer
  New York Times By Andrew Pollack, May 29, 2015
• Lung cancer therapy is 'milestone'
  BBC By James Gallagher, May 30, 2015
• Bristol-Myers Squibb Has A Cancer Breakthrough. Here's Why It Should Cut The Price
  Forbes By Matthey Herper, June 1, 2015